General Information of DTT (ID: TT2I6UX)

DTT Name Beta-N-acetylhexosaminidase (OGA) DTT Info
Gene Name MGEA5

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
5 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY3372689 DMA2M7V Alzheimer disease 8A20 Phase 2 [1]
ASN51 DMZWOYL Alzheimer disease 8A20 Phase 1 [2]
BIIB113 DM7U1AC Alzheimer disease 8A20 Phase 1 [3]
MK 8719 DMFLP21 Progressive supranuclear palsy 8A00.10 Phase 1 [4]
MK-8719 DMETIBD Progressive supranuclear palsy 8A00.10 Phase 1 [5]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 ClinicalTrials.gov (NCT05063539) Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Asceneuron
3 ClinicalTrials.gov (NCT05195008) A Phase 1 Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With an Open-Label Target Occupancy Study of BIIB113 in Healthy Participants. U.S.National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097.